{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:14:31Z","timestamp":1783329271951,"version":"3.54.6"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA244838"],"award-info":[{"award-number":["R01CA244838"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["2P30CA46592"],"award-info":[{"award-number":["2P30CA46592"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011525","name":"Leah's Happy Hearts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011525","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006801","name":"University of Michigan Rackham Graduate School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001794","name":"Pediatric Brain Tumor Foundation of the United States Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010612","name":"ChadTough Defeat DIPG Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010618","name":"Ian's Friends Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017065","name":"Rogel Cancer Center, University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS122536"],"award-info":[{"award-number":["R01-NS122536"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS124167"],"award-info":[{"award-number":["R01-NS124167"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS122165"],"award-info":[{"award-number":["R01-NS122165"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R37-NS144573\\u201301"],"award-info":[{"award-number":["R37-NS144573\\u201301"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201215","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:49:56Z","timestamp":1776815396000},"page":"201215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Brandon L.","family":"McClellan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Pe\u00f1a Agudelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzar A.","family":"Mujeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhakshi","family":"Raghuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Tronrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Calatroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia H.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa Cruz","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud S.","family":"Alghamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sajjakulnukit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas A.","family":"Lyssiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro R.","family":"Lowenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2237-2756","authenticated-orcid":false,"given":"Maria G.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201215_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib4","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/carcin\/bgz134","article-title":"Friend or foe-IDH1 mutations in glioma 10 years on","volume":"40","author":"Huang","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.omton.2026.201215_bib5","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201215_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201215_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201215_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201215_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201215_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139542","article-title":"Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice","volume":"131","author":"Kadiyala","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201215_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3243","article-title":"G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy","volume":"7","author":"Alghamri","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2026.201215_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201215_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaq1427","article-title":"IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response","volume":"11","author":"N\u00fa\u00f1ez","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201215_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.680021","article-title":"Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments","volume":"12","author":"Alghamri","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2026.201215_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fnmol.2018.00082","article-title":"The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas","volume":"11","author":"Mu","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omton.2026.201215_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020229","article-title":"Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201215_bib17","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1158\/2159-8290.CD-19-0541","article-title":"Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity","volume":"9","author":"Li","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201215_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11302-023-09951-0","article-title":"ENTPD1 (CD39) and NT5E (CD73) expression in human glioblastoma: an in silico analysis","volume":"20","author":"Braganhol","year":"2024","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.omton.2026.201215_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.csbj.2015.03.008","article-title":"A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy","volume":"13","author":"Leone","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.omton.2026.201215_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14712598.2022.2157718","article-title":"Gene Therapy for High Grade Glioma: The Clinical Experience","volume":"23","author":"Varela","year":"2023","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.omton.2026.201215_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.631037","article-title":"Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies","volume":"11","author":"Garcia-Fabiani","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib22","article-title":"Nanotechnology in glioblastoma therapy: Advances in drug delivery systems and diagnostic approaches","volume":"102","author":"Qindeel","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.omton.2026.201215_bib23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201215_bib25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1470-2045(23)00347-9","article-title":"Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial","volume":"24","author":"Umemura","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ymthe.2016.10.003","article-title":"Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy","volume":"25","author":"Kamran","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201215_bib27","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","article-title":"Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma","volume":"13","author":"Coy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201215_bib28","first-page":"e52443","article-title":"Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma","author":"Calinescu","year":"2015","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omton.2026.201215_bib29","article-title":"Epigenetic Reprogramming of Autophagy Leads to Uncovering a Novel Therapeutic Target for Mutant IDH1 Astrocytomas","author":"N\u00fa\u00f1ez","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.omton.2026.201215_bib30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201215_bib31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib32","article-title":"Patient-derived cells from recurrent tumors that model the evolution of","volume":"2","author":"Jones","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.omton.2026.201215_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.omton.2026.201215_bib34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201215_bib35","first-page":"S15","article-title":"Enzymatic Methyl-seq: Next Generation Methylomes","volume":"31","author":"Hoppers","year":"2020","journal-title":"J. Biomol. Tech."},{"key":"10.1016\/j.omton.2026.201215_bib36","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","volume":"2","author":"Baylin","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib37","article-title":"The microenvironmental factors induced invasive tumor cells in glioblastoma","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.omton.2026.201215_bib38","doi-asserted-by":"crossref","first-page":"16317","DOI":"10.1074\/jbc.M313890200","article-title":"Extracellular ATP-mediated signaling for survival in hyperoxia-induced oxidative stress","volume":"279","author":"Ahmad","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201215_bib39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/cdd.2013.75","article-title":"Molecular mechanisms of ATP secretion during immunogenic cell death","volume":"21","author":"Martins","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omton.2026.201215_bib40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201215_bib41","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-09-1087","article-title":"Antiglioma immunological memory in response to conditional cytotoxic\/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression","volume":"15","author":"Ghulam Muhammad","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201215_bib42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaneurol.2014.1205","article-title":"IDH mutation in glioma: new insights and promises for the future","volume":"71","author":"Turkalp","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omton.2026.201215_bib43","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-10-1544","article-title":"CD73: a novel target for cancer immunotherapy","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201215_bib44","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1021\/acs.jmedchem.4c02151","article-title":"Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy","volume":"68","author":"Bi","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omton.2026.201215_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212209","article-title":"Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy","volume":"14","author":"Kurago","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201215_bib46","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/1538-7445.AM2024-3737","article-title":"Molecular and early clinical characterization of the anti-CD73 antibody S095024 (Sym024)","volume":"84","author":"Spreafico","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201215_bib47","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201215_bib48","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtho.2022.12.021","article-title":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report","volume":"18","author":"Kim","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib49","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41467-023-42744-y","article-title":"Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial","volume":"14","author":"Buisseret","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201215_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134386","article-title":"Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration","volume":"5","author":"Ott","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201215_bib51","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1593\/neo.11024","article-title":"B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory\/conditionally cytotoxic therapy for glioblastoma","volume":"13","author":"Candolfi","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.omton.2026.201215_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000010","article-title":"HMGB1 mediates endogenous TLR2 activation and brain tumor regression","volume":"6","author":"Curtin","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.omton.2026.201215_bib53","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1158\/1078-0432.CCR-11-0915","article-title":"Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design","volume":"17","author":"Mineharu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201215_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101357","article-title":"Murine brain tumor microenvironment immunophenotyping using mass cytometry","volume":"3","author":"McClellan","year":"2022","journal-title":"STAR Protoc."},{"key":"10.1016\/j.omton.2026.201215_bib55","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201215_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.omton.2026.201215_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/neuonc\/now247","article-title":"GlioVis data portal for visualization and analysis of brain tumor expression datasets","volume":"19","author":"Bowman","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201215_bib58","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-15-2888","article-title":"Survival and Proliferation of Neural Progenitor-Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12\/CXCR4 Autocrine-Positive Feedback Mechanism","volume":"23","author":"Calinescu","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:17:15Z","timestamp":1783325835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926000913"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201215","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.11.11.687828","asserted-by":"object"}]},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201215"}}